Biomedical papers, 2016 (vol. 160), issue 3

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016, 160(3):372-377 | 10.5507/bp.2016.044

The long-term effects of probiotics in the therapy of ulcerative colitis: A clinical study

Vincenzo Davide Palumboa,b, Marcello Romeoc, Antonella Marino Gammazzaa,c, Francesco Carinic,d, Provvidenza Damianid, Giuseppe Damianoc, Salvatore Buscemic, Attilio Ignazio Lo Montec,d, Alice Gerges-Geageac,e, Abdo Jurjuse, Giovanni Tomaselloa,c,d
a Euro-Mediterranean Institute of Science and Technology (IEMEST), Palermo, Italy
b Department of Surgical, Oncological and Stomatological Disciplines, School of Medicine, University of Palermo, Palermo, Italy
c Department of Experimental Biomedicine and Clinical Neuroscience, School of Medicine, University of Palermo, Palermo, Italy
d P. Giaccone University Hospital, Palermo, Italy
e Department of Anatomy, Cell Biology and Physiology, School of Medidcine, Aamerican University of Beirut, Beirut, Lebanon

Aim: Intestinal dysbiosis seems to be the leading cause of inflammatory bowel diseases, and probiotics seems to represent the proper support against their occurrence. Actually, probiotic blends and anti-inflammatory drugs represent a weapon against inflammatory bowel diseases. The present study evaluates the long-term (2 years) effects of combination therapy (mesalazine plus a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4) on ulcerative colitis activity.

Method: Sixty patients with moderate-to-severe ulcerative colitis were enrolled: 30 of them were treated with a single daily oral administration of mesalazine 1200 mg; 30 patients received a single daily oral administration of mesalazine 1200 mg and a double daily administration of a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4. The treatment was carried out for two years and the clinical response evaluated according to the Modified Mayo Disease Activity Index.

Results: All patients treated with combination therapy showed better improvement compared to the controls. In particular, the beneficial effects of probiotics were evident even after two years of treatment.

Conclusions: A long-term treatment modality of anti-inflammatory drugs and probiotics is viable and could be an alternative to corticosteroids in mild-to moderate ulcerative colitis.

Keywords: bifidobacteria, inflammatory bowel diseases, lactobacilli, microbiota, ulcerative colitis

Received: January 18, 2016; Accepted: August 10, 2016; Prepublished online: September 13, 2016; Published: September 20, 2016


References

  1. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142:46-54. Go to original source... Go to PubMed...
  2. Cotran RS, Collins T, Robbins SL, Kumar V. Pathologic Basis of Disease, 3rd edn. Philadelphia: WB Saunders; 1998.
  3. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007;448:427-34. Go to original source... Go to PubMed...
  4. Almeida MG, Kiss DR, Zilberstein B, Quintanilha AG, Teixeira MG, Habr-Gama A. Intestinal mucosa-associated microflora in ulcerative colitis patients before and after restorative proctocolectomy with an ileoanal pouch. Dis Colon Rectum 2008;51:1113-9. Go to original source... Go to PubMed...
  5. Hildebrand F, Nguyen TL, Brinkman B, Yunta RG, Cauwe B, Vandenabeele P, Liston A, Raes J. Inflammation-associated enterotypes, host genotype cage and inter-individual effects drive gut microbiota variation in common laboratory mice. Genome Biol 2013;14:R4. Go to original source... Go to PubMed...
  6. Tursi A, Brandimarte G, Papa A, Giglio A, Elisei W, Giorgetti GM, Forti G, Morini S, Hassan C, Pistoia MA, Modeo ME, Rodino' S, D'Amico T, Sebkova L, Sacca' N, Di Giulio E, Luzza F, Imeneo M, Larussa T, Di Rosa S, Annese V, Danese S, Gasbarrini A. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double blind, randomized, placebo-controlled study. Am J Gastroenterol 2010;105:2218-27. Go to original source... Go to PubMed...
  7. Tomasello G, Palumbo VD, Miceli A, Sinagra E, Bruno A, Abruzzo A, Cappello F, Patti AM, Giglio RM, Damiani P, Tomasello R, Noto M, Arculeo VM, Accardo MF, Lo Monte AI. Probiotics and conventional therapy: new frontiers in therapeutic approach in articular manifestations of IBD. Progr Nutr 2014;16:176-87.
  8. Sinagra E, Tomasello G, Cappello F, Leone A, Cottone M, Bellavia M, Rossi F, Facella T, Damiani P, Zeenny MN, Damiani F, Abruzzo A, Damiano G, Palumbo VD, Cocchi M, Jurjus A, Spinelli G, Lo Monte AI, Raimondo D. Probiotics, prebiotics and synbiotics in inflammatory bowel diseases: state-of-the-art and new insights. J Biol Regul Homeost Agents 2013;27:919-33. Go to PubMed...
  9. Kvasnovsky CL, Bjarnason I, Papagrigoriadis S. What colorectal surgeons should know about probiotics: a review. Colorectal Dis 2015;17:840-8. Go to original source... Go to PubMed...
  10. Mack DR. Probiotics in inflammatory bowel diseases and associated conditions. Nutrients 2011;3:245-64. Go to original source... Go to PubMed...
  11. D'Haens GR, Sartor RB, Silverberg MS, Petersson J, Rutgeerts P. Future directions in inflammatory bowel disease management. J Crohns Colitis 2014;8:726-34. Go to original source... Go to PubMed...
  12. Langan RC, Gotsch PB, Krafczyk MA, Skillinge DD. Ulcerative colitis: diagnosis and treatment. Am Fam Physician 2007;76:1323-30. Go to PubMed...
  13. MacDermott RP, Green JA, Ashley CC. What is the optimal therapy for severe ulcerative colitis? Inflamm Bowel Dis 2008;14:S228-31. Go to original source... Go to PubMed...
  14. Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 2009;104:437-43. Go to original source... Go to PubMed...
  15. Scherl EJ, Pruitt R, Gordon GL, Lamet M, Shaw A, Huang S, Mareya S, Forbes WP. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study. Am J Gastroenterol 2009;104:1452-9. Go to original source... Go to PubMed...
  16. Bellavia M, Damiano G, Gioviale MC, Palumbo VD, Cacciabaudo F, Buscemi G, Lo Monte AI. Abnormal expansion of segmented filamentous bacteria in the gut: a role in pathogenesis of chronic inflammatory intestinal diseases? Rev Microbiol 2011;22:45-7. Go to original source...
  17. Tomasello G, Bellavia M, Palumbo VD, Gioviale MC, Damiani P, Lo Monte AI . From gut microflora imbalance to mycobacteria infection: is there a relationship with chronic intestinal inflammatory diseases? Ann Ital Chir 2011;82:361-8. Go to PubMed...
  18. Rodolico V, Tomasello G, Zerilli M, Martorana A, Pitruzzella A, Gammazza AM, David S, Zummo G, Damiani P, Accomando S, Conway de Macario E, Macario AJ, Cappello F. Hsp60 and Hsp10 increase in colon mucosa of Crohn's disease and ulcerative colitis. Cell Stress Chaperones 2010;15:877-84. Go to original source... Go to PubMed...
  19. Tomasello G, Rodolico V, Zerilli M, Martorana A, Bucchieri F, Pitruzzella A, Marino Gammazza A, David S, Rappa F, Zummo G, Damiani P, Accomando S, Rizzo M, de Macario EC, Macario AJ, Cappello F. Changes in immunohistochemical levels and subcellular localization after therapy and correlation and colocalization with CD68 suggest a pathogenetic role of Hsp60 in ulcerative colitis. Appl Immunohistochem Mol Morphol 2011;19:552-61. Go to original source... Go to PubMed...
  20. Tomasello G, Sciumé C, Rappa F, Rodolico V, Zerilli M, Martorana A, Cicero G, De Luca R, Damiani P, Accardo FM, Romeo M, Farina F, Bonaventura G, Modica G, Zummo G, Conway de Macario E, Macario AJ, Cappello F. Hsp10, Hsp70, and Hsp90 immunohistochemical levels change in ulcerative colitis after therapy. Eur J Histochem 2011;55:e38. Go to original source... Go to PubMed...
  21. Yoshimatsu Y, Yamada A, Furukawa R, Sono K, Osamura A, Nakamura K, Aoki H, Tsuda Y, Hosoe N, Takada N, Suzuki Y.Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis. World J Gastroenterol 2015;21:5985-94. Go to PubMed...
  22. Chen WX, Ren LH, Shi RH. Enteric micobiota leads to new therapeutic strategies for ulcerative colitis. World J Gastroenterol 2014;20:15657-63. Go to original source... Go to PubMed...
  23. Saez-Lara MJ, Gomez-Llorente C, Plaza-Diaz J, Gil A.The role of probiotic lactic acid bacteria and bifidobacteria in the prevention and treatment of inflammatory bowel disease and other related diseases: a systematic review of randomized human clinical trials. Biomed Res Int 2015;2015:505878. Go to original source... Go to PubMed...
  24. Strisciuglio C, Miele E, Giugliano FP, Vitale S, Andreozzi M, Vitale A, Catania MR, Staiano A, Troncone R, Gianfrani C. Probiotic bacteria enhance antigen sampling and processing by dendritic cells in pediatric Inflammatory Bowel Disease. Dig Liver Dis 2015;21:1491-8.
  25. Tralongo P, Tomasello G, Sinagra E, Damiani P, Leone A, Palumbo VD, Giammanco M, Di Majo D, Damiani F, Abruzzo A, Bruno A, Cassata G, Cicero L, Noto M, Tomasello R, Lo Monte AI. The role of butyric acid as a protective agent against inflammatory bowel diseases. EMBJ 2014;9:24-35.
  26. Sandborn WJ, Korzenik J, Lashner B, Leighton JA, Mahadevan U, Marion JF, Safdi M, Sninsky CA, Patel RM, Friedenberg KA, Dunnmon P, Ramsey D, Kane S. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology 2010;138:1286-96. Go to original source... Go to PubMed...
  27. Collins JK. Demonstration of functional properties of probiotic lactic acid bacteria. Ind Latte 2001;37:39-61.
  28. You HJ, Oh DK, Ji GE. Anticancerogenic effect of a novel chiroinositol-containing polysaccharide from Bifidobacterium bifidum BGN4. FEMS Microbiol Lett 2004;240:131-6. Go to original source... Go to PubMed...
  29. Bressler B, Marshall JK, Bernstein CN, Bitton A, Jones J, Leontiadis GI, Panaccione R, Steinhart AH, Tse F, Feagan B, Toronto Ulcerative Colitis Consensus Group. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology 2015;148:1035-58. Go to original source... Go to PubMed...
  30. Ishikawa H, Akedo I, Umesaki Y, Tanaka R, Imaoka A, Otani T. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr 2003;22:56-63. Go to original source... Go to PubMed...
  31. Kato K, Mizuno S, Umesaki Y, Ishii Y, Sugitani M, Imaoka A, Otsuka M, Hasunuma O, Kurihara R, Iwasaki A, Arakawa Y. Randomized placebocontrolled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther 2004;20:1133-41. Go to original source... Go to PubMed...
  32. Wildt S, Nordgaard I, Hansen U, Brockmann E, Rumessen JJ. A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. J Crohns Colitis 2011;5:115-21. Go to original source... Go to PubMed...
  33. Cui HH, Chen CL, Wang JD, Yang YJ, Cun Y, Wu JB, Liu YH, Dan HL, Jian YT, Chen XQ. Effects of probiotic on intestinal mucosa of patients with ulcerative colitis. World J Gastroenterol 2004;10:1521-5. Go to original source... Go to PubMed...
  34. Zocco MA, dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, Candelli M, Novi M, Rigante D, Cazzato IA, Ojetti V, Armuzzi A, Gasbarrini G, Gasbarrini A. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 2006:23:1567-74. Go to original source... Go to PubMed...
  35. Hegazy SK, El-Bedewy MM. Effect of probiotics on pro-inflammatory cytokines and NF-κB activation in ulcerative colitis. World J Gastroenterol 2010;16:4145-51. Go to original source... Go to PubMed...
  36. Oliva S, Di Nardo G, Ferrari F, Mallardo S, Rossi P, Patrizi G, Cucchiara S, Stronati L. Randomised clinical trial: the effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis. Aliment Pharmacol Ther 2012;35:327-34. Go to original source... Go to PubMed...
  37. D'Incà R, Barollo M, Scarpa M, Grillo AR, Brun P, Vettorato MG, Castagliuolo I, Sturniolo GC. Rectal administration of Lactobacillus casei DG modifies flora composition and toll-like receptor expression in colonic mucosa of patients with mild ulcerative colitis. Dig Dis Sci 2011;56:1178-87. Go to original source... Go to PubMed...